Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
source: pixabay.com

Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®

This week Neurocrine Biosciences announced the results of its KINECT®-4 Phase 3 study of INGREZZA® capsules. Results of the trial were published in the Journal of Clinical Psychopharmacology. A long-term…

Continue Reading Tardive Dyskinesia: Phase 3 Study Results Indicate Improvement with Use of INGREZZA®
Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
shutterstock.com

Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis

Cartesian Therapeutics, Inc., a biotechnology company, recently announced that the FDA has awarded the Regenerative Medicine Advanced Therapy (RMAT) designation to its lead product, Descartes-08, to treat myasthenia gravis (MG).…

Continue Reading Cartesian Therapeutics Earns Regenerative Medicine Advanced Therapy Designation for Myasthenia Gravis
Healthy Skin Transplants Could Successfully Treat Epidermolytic Ichthyosis and Ichthyosis with Confetti
source: shutterstock.com

Healthy Skin Transplants Could Successfully Treat Epidermolytic Ichthyosis and Ichthyosis with Confetti

You've heard of kidney transplants. You've heard of liver transplants. And you've probably even heard of lung transplants. But have you heard of skin transplants? In many cases, skin transplants…

Continue Reading Healthy Skin Transplants Could Successfully Treat Epidermolytic Ichthyosis and Ichthyosis with Confetti